Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on nebulized solutions for chronic obstructive pulmonary disease and asthma, closed a $30M Series B financing. Participants include Novo Ventures, Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners.

Imagen Biotech (United Kingdom) a commercial-stage biotechnology assay company focused on analysis of signal transduction pathways and target validation, closed a $40M Series A financing. Participants include SV Life Sciences, Novo Ventures and Fidelity Biosciences.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include SR One, MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

HTG (Tuscon, AZ) a commercial-stage molecular technology company focused on gene expression profiling, miRNA and mRNA measurement, translational medicine and diagnostic applications, closed a $15.7M Series D financing. Participants include Novo Ventures, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures.

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.

Funxional Therapeutics (United Kingdom) a clinical-stage small molecule company focused on asthma, COPD and other respiratory disorders, closed a $12.2M Series B financing. Participants include Ventech, Index Ventures and Novo Ventures.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

« Previous Entries  Next Page »

to top of page...